Lucentis Alternatives Compared
| Lucentis (ranibizumab) | Eylea (aflibercept) | Syfovre (pegcetacoplan) |
|
|---|
| Lucentis (ranibizumab) | Eylea (aflibercept) | Syfovre (pegcetacoplan) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Macular Degeneration, Myopic Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema, Macular Edema, Macular Edema Following Retinal Vein Occlusion. Lucentis may... View more |
Prescription only
Eylea and Eylea HD both contain aflibercept and are VEGF (vascular endothelial growth factor) inhibitors that used to treat retinal eye diseases that may affect your vision. These include neovascular... View more |
Prescription only
Prescribed for Geographic Atrophy, Macular Degeneration. Syfovre may also be used for purposes not listed in this medication guide. |
Related suggestions Macular Degeneration
Popular comparisons
|
|||||||||||||||||||||||
| More about Lucentis (ranibizumab) | More about Eylea (aflibercept) | More about Syfovre (pegcetacoplan) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Lucentis has an average rating of 6.1 out of 10 from a total of 15 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 27% reported a negative effect. |
Eylea has an average rating of 7.1 out of 10 from a total of 74 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 19% reported a negative effect. |
Syfovre has an average rating of 8.2 out of 10 from a total of 6 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Lucentis side effects |
View all Eylea side effects |
View all Syfovre side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Lucentis prices |
View all Eylea prices |
View all Syfovre prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other ranibizumab brands include: Byooviz, Cimerli, Susvimo | Other aflibercept brands include: Ahzantive, Enzeevu, Eylea HD, Opuviz, Pavblu, Yesafili |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
216 hours |
144 hours |
108 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 2 drugs are known to interact with Lucentis:
|
A total of 1 drugs are known to interact with Eylea:
|
A total of 2 drugs are known to interact with Syfovre:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Eylea
Eylea is used to treat neovascular (wet) age-related macular degeneration (AMD), macular edema ...
Syfovre
Syfovre (pegcetacoplan) treatment for geographic atrophy (GA) a form of dry age-related macular ...
Izervay
Izervay (avacincaptad pegol) is used for treating geographic atrophy (GA) due to age-related ...
Vabysmo
Vabysmo eye injection is used to treat eye diseases neovascular (wet) age-related macular ...
Eylea HD
Eylea HD is used to treat neovascular (wet) age-related macular degeneration (AMD), diabetic ...
Pavblu
Pavblu (aflibercept-ayyh) is a biosimilar to Eylea that may be used to treat the following eye ...
Yesafili
Yesafili (aflibercept-jbvf) is an interchangeable biosimilar to Eylea that may be given by ...
Faricimab ophthalmic
Faricimab ophthalmic is used for diabetic macular edema, macular degeneration, macular edema ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.